LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST).

The live events and replays of the presentations can be accessed via the Events page of the Company’s website at .

About Lexicon Pharmaceuticals 

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit . 

For Investor and Media Inquiries: 

Lisa DeFrancesco  

Lexicon Pharmaceuticals, Inc. 

 



EN
11/11/2025

Underlying

LXRXLexicon Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Announces Pricing of Approximately $94.6 Million Public Offeri...

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...

January 30, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Announces Proposed Public Offering of Common Stock

Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...

January 29, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27,...

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...

January 23, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting wi...

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...

January 21, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the...

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch